Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
50%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)
Other(2)

Detailed Status

unknown2
Completed2
Withdrawn2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

active_not_recruiting113%
unknown225%
completed225%
withdrawn225%
recruiting113%

Recent Activity

2 active trials
Showing 5 of 8
withdrawn

Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

NCT07475923
active_not_recruitingphase_2

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

NCT04669496
recruitingphase_2

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

NCT04268121
withdrawnphase_2

A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer

NCT05574712
completed

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

NCT06129812
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07475923

Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

Withdrawn
NCT04669496Phase 2

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Active Not Recruiting
NCT04268121Phase 2

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting
NCT05574712Phase 2

A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer

Withdrawn
NCT06129812

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Completed
NCT05495308

"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".

Completed
NCT04506281Phase 2

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Unknown
NCT03351959

Complete Pathologic Response Rectal Cancers

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8